Stockscreener 앱 받기
1.06
0.95%
0.01
시간 외 거래:
1.05
-0.01
-0.94%
전일 마감가:
$1.05
열려 있는:
$1.04
하루 거래량:
60,507
Relative Volume:
0.15
시가총액:
$5.52M
수익:
-
순이익/손실:
$-18.68M
주가수익비율:
-0.1433
EPS:
-7.3948
순현금흐름:
$-15.70M
1주 성능:
-1.85%
1개월 성능:
-25.35%
6개월 성능:
-80.52%
1년 성능:
-93.46%
1일 변동 폭
$1.02
$1.0929
1주일 범위
$1.0016
$1.0929
52주 변동 폭
$0.9523
$19.80
Fibrobiologics Inc Stock (FBLG) Company Profile
명칭
Fibrobiologics Inc
전화
281-671-5150
주소
455 E. MEDICAL CENTER BLVD, HOUSTON
Compare FBLG vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FBLG
Fibrobiologics Inc
|
1.06 | 5.47M | 0 | -18.68M | -15.70M | -7.3948 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fibrobiologics Inc Stock (FBLG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-12 | 개시 | Rodman & Renshaw | Buy |
| 2024-10-30 | 개시 | H.C. Wainwright | Buy |
| 2024-09-24 | 개시 | Maxim Group | Buy |
Fibrobiologics Inc 주식(FBLG)의 최신 뉴스
FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting - Sahm
Fibroblast cell therapy avoided psoriasis relapse in FibroBiologics mouse study - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
FBLG Stock Price, Quote & Chart | FIBROBIOLOGICS INC (NASDAQ:FBLG) - ChartMill
FBLG Stock Chart | FIBROBIOLOGICS INC (NASDAQ:FBLG) - ChartMill
Exclusive: FibroBiologics moves forward with human trial for diabetic foot ulcer therapy - MSN
FibroBiologics files patent for oral fibroblast delivery system - Investing.com UK
FibroBiologics files patent for oral fibroblast delivery system By Investing.com - Investing.com Australia
New oral cell therapy platform aimed at gut diseases from IBS to Crohn's - Stock Titan
Exclusive: FibroBiologics targets 2026 data readout after trial progress for diabetic foot ulcer study - MSN
TradingKey - TradingKey
Fibrobiologics explores use of fibroblast platform for hantavirus - BioWorld News
FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus - GlobeNewswire
Severe Hantavirus syndrome lacks drugs, FibroBiologics tests fibroblast therapy - Stock Titan
FibroBiologics | 424B5: Prospectus - Moomoo
FBLG | FibroBiologics, Inc. Common Stock Executive Compensation - Quiver Quantitative
FibroBiologics, Inc. Files Form 8-K Announcing Material Definitive Agreement and Company Details - Minichart
FibroBiologics Expands At-The-Market Equity Offering Capacity - TipRanks
FibroBiologics Grants Stock Options to Key Executives - The Globe and Mail
FibroBiologics (NASDAQ: FBLG) expands $7.5M at-the-market stock offering - Stock Titan
FibroBiologics begins patient enrollment for diabetic foot ulcer trial By Investing.com - Investing.com Australia
FibroBiologics (NASDAQ: FBLG) expands ATM capacity to $7.5M under S-3 - Stock Titan
EXCLUSIVE: FibroBiologics Targets 2026 Data Readout After Trial Progress For Diabetic Foot Ulcer Study - Sahm
FibroBiologics | DEFA14A: Others - Moomoo
FibroBiologics begins patient enrollment for diabetic foot ulcer trial - Investing.com
FibroBiologics CEO Issues Letter to Shareholders - markets.businessinsider.com
33 million people have diabetic foot ulcers. FibroBiologics starts a trial - Stock Titan
FibroBiologics grants stock options to CEO Pete O’Heeron and CFO Jason D. Davis - TradingView
[8-K] FibroBiologics, Inc. Reports Material Event - Stock Titan
FibroBiologics (FBLG) seeks approval for warrant shares and 2026 equity incentive plan - Stock Titan
FibroBiologics reports preclinical burn wound treatment results _newTouch_By Investing.com - Investing.com South Africa
FibroBiologics | 4: Statement of changes in beneficial ownership of securities-Officer Davis Jason - Moomoo
FibroBiologics | 4: Statement of changes in beneficial ownership of securities-Officer GARCIA RUBEN A - Moomoo
FibroBiologics | 4: Statement of changes in beneficial ownership of securities-Officer O'HEERON PETE - Moomoo
FibroBiologics reports preclinical burn wound treatment results By Investing.com - Investing.com South Africa
Fibrobiologics Inc (FBLG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):